Ellagic acid ameliorates high fructose-induced hyperuricemia and non-alcoholic fatty liver in Wistar rats: Focusing on the role of C1q/tumor necrosis factor-related protein-3 and ATP citrate lyase

Elseweidy, Mohamed M.; Elesawy, Ahmed E.; Sobh, Mohammed S.; Elnagar, Gehad M.

doi:10.1016/j.lfs.2022.120751

Cited by 8 publications

(3 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, an initial evaluation of ferulic acid's anticancer activity in HepG2 cells demonstrated its role in inhibiting tumor cell proliferation through inducing apoptosis and autophagy . High-fructose-induced hyperuricemia and NAFLD C1q /CTRP3(+)/ACL(-) (Elseweidy et al, 2022) Ferulic acid Cecal ligation and perforation (CLP)-induced and lipopolysaccharide (LPS)-induced ALI GSK-3β/CREB/ NF-κB(-) (Cao et al, 2021) Aflatoxin B1-induced liver damage CYP450(-)/Nrf2/GST(+) (Wang, He, et al, 2021) CCl4-induced hepatic fibrosis TGF-β1/ Smads(-) (Mu et al, 2018) HCHF-induced NASH ROCK/NF-κB(-) (Wei et al, 2021) HFD-induced NAFLD PPARα(+) (Luo et al, 2022) Chlorogenic acid CCl4-induced liver fibrosis and inflammation TLR4/MyD88/NF-κB(-) (Shi et al, 2013) ANIT-induced liver injury STAT3/NF-κB(-) (Tan et al, 2016) CCl4-induced liver injury NLRP3(-)/Nrf2(+) (Shi et al, 2018) HFD-induced NAFLD TLR4(-) (Shi et al, 2021) MCDD diet-induced NAFLD LPS-TLR4-MyD88(-) (Gu et al, 2023) MCD diet-induced NAFLD ECM/HSCs(-) (Miao et al, 2022) HCC cells Hep-G2 and Huh-7 NF-κB(-)/BBC3(+) (Jiang et al, 2021) Gallic acid aHSCs TRADD/RIP3(+) (Chang et al, 2015) HFD-induced NAFLD rats and palmitic acid (PA) and oleic acid (OA)-treated hepatocytes AMPK/ACC/PPARα(-) (J. Fructose-induced NAFLD AMPK/SREBP-1/ ACC/ FASN axis (-) (Lu et al, 2023)…”

Section: Ferulic Acidmentioning

confidence: 99%

“…Another study suggested that ellagic acid treatment protected against NAFLD by modulating lipid metabolism through the activation of AMPK signaling (ALTamimi et al, 2022). Furthermore, a recent study showed that ellagic acid can alleviate high‐fructose intake diet‐induced hyperuricemia in rats with NAFLD by activating C1q/tumor necrosis factor‐related protein‐3 (CTRP3) and inhibiting ATP citrate lyase (ACL) (Elseweidy et al, 2022). While the effects of ellagic acid on HCC, such as antiangiogenesis, anti‐inflammatory, and antiproliferative actions, have been observed, there is still a need to explore new signaling pathways (Aishwarya et al, 2021).…”

Section: Mechanisms Of Polyphenolic Compounds Protect Against Hepatic...mentioning

confidence: 99%

See 1 more Smart Citation

Human diet‐derived polyphenolic compounds and hepatic diseases: From therapeutic mechanisms to clinical utilization

Hu,

Zhang,

Wei

et al. 2023

Phytotherapy Research

View full text Add to dashboard Cite

This review focuses on the potential ameliorative effects of polyphenolic compounds derived from human diet on hepatic diseases. It discusses the molecular mechanisms and recent advancements in clinical applications. Edible polyphenols have been found to play a therapeutic role, particularly in liver injury, liver fibrosis, NAFLD/NASH, and HCC. In the regulation of liver injury, polyphenols exhibit anti‐inflammatory and antioxidant effects, primarily targeting the TGF‐β, NF‐κB/TLR4, PI3K/AKT, and Nrf2/HO‐1 signaling pathways. In the regulation of liver fibrosis, polyphenolic compounds effectively reverse the fibrotic process by inhibiting the activation of hepatic stellate cells (HSC). Furthermore, polyphenolic compounds show efficacy against NAFLD/NASH by inhibiting lipid oxidation and accumulation, mediated through the AMPK, SIRT, and PPARγ pathways. Moreover, several polyphenolic compounds exhibit anti‐HCC activity by suppressing tumor cell proliferation and metastasis. This inhibition primarily involves blocking Akt and Wnt signaling, as well as inhibiting the epithelial‐mesenchymal transition (EMT). Additionally, clinical trials and nutritional evidence support the notion that certain polyphenols can improve liver disease and associated metabolic disorders. However, further fundamental research and clinical trials are warranted to validate the efficacy of dietary polyphenols.

show abstract

Section: Ferulic Acidmentioning

confidence: 99%

Section: Mechanisms Of Polyphenolic Compounds Protect Against Hepatic...mentioning

confidence: 99%

Human diet‐derived polyphenolic compounds and hepatic diseases: From therapeutic mechanisms to clinical utilization

Hu,

Zhang,

Wei

et al. 2023

Phytotherapy Research

View full text Add to dashboard Cite

show abstract

“…Similarly, ellagic acid alleviates the liver damage in CCl 4 -induced rat model by its antioxidation and antiapoptosis [83]. Also, ellagic acid mitigates the liver damage by suppressing oxidative stress and hepatic lipogenic enzymes in high-fructose–induced rat NALFD model, and suppressing TLR and MAPK/NFκB signaling pathways in ConA-induced mouse immune model [84,85].…”

Section: Natural Compounds Derived From Edible Plantsmentioning

confidence: 99%

A review of edible plant-derived natural compounds for the therapy of liver fibrosis

Wang

Niu

et al. 2022

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

Liver fibrosis has a high incidence worldwide and is the common pathological basis of many chronic liver diseases. Liver fibrosis is caused by the excessive deposition of extracellular matrix and concomitant collagen accumulation in livers and can lead to the development of liver cirrhosis and even liver cancer. A large number of studies have provided evidence that liver fibrosis can be blocked or even reversed by appropriate medical interventions. However, the antifibrosis drugs with ideal clinical efficacy are still insufficient. The edible plant-derived natural compounds have been reported to exert effective antifibrotic effects with few side-effects, representing a kind of promising source for the treatment of liver fibrosis. In this article, we reviewed the current progress of the natural compounds derived from dietary plants in the treatment of liver fibrosis, including phenolic compounds (capsaicin, chlorogenic acid, curcumin, ellagic acid, epigallocatechin-3-gallate, resveratrol, sinapic acid, syringic acid, vanillic acid and vitamin E), flavonoid compounds (genistein, hesperidin, hesperetin, naringenin, naringin and quercetin), sulfur-containing compounds (S-allylcysteine, ergothioneine, lipoic acid and sulforaphane) and other compounds (betaine, caffeine, cucurbitacin B, lycopene, α-mangostin, γ-mangostin, ursolic acid, vitamin C and yangonin). The pharmacological effects and related mechanisms of these compounds in in-vivo and in-vitro models of liver fibrosis are focused.

show abstract

Design, optimization, and in-vivo performance of glipizide-loaded O-carboxymethyl chitosan nanoparticles in insulin resistant/type 2 diabetic rat model

El-Dakroury

Amin

2023

Journal of Drug Delivery Science and Technology

View full text Add to dashboard Cite

Ellagic acid ameliorates high fructose-induced hyperuricemia and non-alcoholic fatty liver in Wistar rats: Focusing on the role of C1q/tumor necrosis factor-related protein-3 and ATP citrate lyase

Cited by 8 publications

References 70 publications

Human diet‐derived polyphenolic compounds and hepatic diseases: From therapeutic mechanisms to clinical utilization

Human diet‐derived polyphenolic compounds and hepatic diseases: From therapeutic mechanisms to clinical utilization

A review of edible plant-derived natural compounds for the therapy of liver fibrosis

Design, optimization, and in-vivo performance of glipizide-loaded O-carboxymethyl chitosan nanoparticles in insulin resistant/type 2 diabetic rat model

Contact Info

Product

Resources

About